Pulmonary resection is a common surgical intervention primarily performed to treat lung cancer and other serious pulmonary conditions. Despite advances in surgical techniques and postoperative care, complications such as hospital readmission remain a challenge, affecting patient quality of life and healthcare resource utilization. Identifying reliable predictors for adverse postoperative outcomes has therefore become a focal point in improving patient prognosis and healthcare strategies.

The 6-minute walk test, a widely accepted measure of functional capacity, involves assessing the distance a patient can walk on a flat, hard surface in six minutes. It is a simple yet powerful tool reflecting cardiopulmonary and muscular endurance. In this study, a cohort of 99 patients undergoing pulmonary resection between 2015 and 2018 was evaluated for changes in 6MWT distance before and after surgery, to investigate the relationship between decreased physical performance and hospital readmission risk.

Subjects were stratified into two groups based on the degree of decline in their 6MWT distance following surgery. The “decreased group” experienced a reduction of 30 meters or more, while the “unchanged group” had less than a 30-meter decline. The distinction was essential to observe how varying degrees of postoperative functional loss influenced clinical outcomes, particularly hospital readmission rates and mortality.

Significantly, the study found that the decreased group, comprising 53 patients, had notably higher rates of hospital readmission compared to the unchanged group of 46 patients. Specifically, the decreased group saw 14 readmissions, whereas the unchanged group recorded only five. Statistical analysis confirmed that this disparity was significant, with a p-value of 0.04, indicating a strong association between reduced walk distance and readmission risk.

Although overall survival between the two groups did not differ markedly, the data suggested a trend towards lower survival in patients with decreased 6MWT distances, indicated by a borderline p-value of 0.07. This nuanced finding underscores the clinical relevance of functional decline post-surgery, not only as a marker for short-term complications but possibly affecting longer-term survival outcomes as well.

To delve deeper into risk stratification, the researchers employed a Cox proportional hazards model, which affirmed that a greater than 30-meter decrease in 6MWT distance independently predicted hospital readmission. The hazard ratio calculated was 3.05 with a 95% confidence interval ranging from 1.02 to 9.15, solidifying the magnitude of risk associated with postoperative functional decline.

Importantly, the study noted that other clinicopathologic factors, such as patient demographics and disease characteristics, did not significantly differ between groups except for operative time, suggesting that the observed differences in outcomes were closely linked to physical capacity changes rather than baseline patient conditions.

The implications of these findings are profound. Surgeons and clinicians could implement pre- and post-surgery 6MWT assessments as part of routine care to identify patients at elevated risk for complications. Early identification would enable tailored interventions, such as enhanced pulmonary rehabilitation, closer follow-up, or preemptive support services, aimed at reducing readmission rates and improving recovery trajectories.

Furthermore, the 6-minute walk test’s non-invasive, cost-effective nature renders it an accessible option for clinics worldwide, even in resource-limited settings. Standardizing its use could foster better comparative research across institutions and contribute to developing guidelines for postoperative care in thoracic surgery.

This research also sheds light on the potential pathophysiological mechanisms underlying postoperative decline. Pulmonary resection often results in reduced lung volume and compromised respiratory efficiency, which might contribute directly to diminished exercise tolerance. The deconditioning that follows surgery, coupled with possible complications like infections or cardiac stress, can exacerbate functional decline and justify increased surveillance in vulnerable patients.

Though the study was retrospective and limited to a single center with a relatively small sample, its findings pave the way for larger, prospective investigations. Future studies could assess whether targeted rehabilitation interventions can mitigate the loss of 6MWT distance and ultimately reduce readmission frequency, improving both patient outcomes and healthcare system burdens.

Moreover, exploring the interplay between 6MWT changes and biomarkers of inflammation or cardiopulmonary function could enrich understanding and refine risk models. Such integrative approaches may pinpoint patients who would benefit most from aggressive postoperative management strategies.

Given the rising incidence of lung cancer globally and the increasing utilization of pulmonary resection, optimizing postoperative care remains a public health priority. This study’s revelation that a straightforward physical performance metric can predict readmission risk offers a tangible tool to clinicians aiming to enhance patient care pathways.

In conclusion, the demonstrated association between decreased 6-minute walk distance post-pulmonary resection and increased hospital readmission represents an important advancement in perioperative medicine. It underscores the critical role of functional assessment in tailoring treatment and surveillance plans, potentially transforming standard clinical practice and ultimately improving patient quality of life.

Subject of Research: Postoperative prognosis and hospital readmission risk linked to changes in 6-minute walk distance after pulmonary resection.

Article Title: Decreased 6-minute walk distance after pulmonary resection increases the risk of postoperative hospital re-admission: a retrospective cohort study

Article References:
Maniwa, H., Naito, M., Ono, M. et al. Decreased 6-minute walk distance after pulmonary resection increases the risk of postoperative hospital re-admission: a retrospective cohort study. BMC Cancer 25, 1397 (2025). https://doi.org/10.1186/s12885-025-14821-6

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14821-6

The retrospective cohort study analyzed data from nearly 8,000 adults with severe obesity, defined by an average body mass index exceeding 39, treated with either semaglutide or tirzepatide between 2021 and 2023. A substantial proportion of the cohort also had prediabetes, a condition characterized by elevated blood glucose levels that often precedes the onset of type 2 diabetes. The investigators followed these patients through December 2024, documenting patterns of medication adherence, dosing strategies, and associated clinical outcomes relating to both weight reduction and glycemic control.

One of the pivotal observations emerging from the research was the notable prevalence of early discontinuation, with over 20% of patients ceasing treatment within the first three months. An additional 32% halted therapy later, within one year of initiation. Such persistence rates contrast sharply with those typically reported in clinical trials, where adherence is rigorously supported and monitored. Furthermore, more than 80% of patients who remained on treatment were maintained on dosages equal to or lower than 1 mg daily for semaglutide and 7.5 mg weekly for tirzepatide, respectively. This dosage pattern diverges from the higher maintenance doses commonly employed in trials, thereby potentially limiting therapeutic efficacy.

When examining weight loss outcomes, the study revealed a graded relationship between treatment persistence, dosage, and the extent of body weight reduction. Participants who discontinued therapy early lost an average of just 3.6% of their body weight after one year, while those who discontinued late experienced a 6.8% reduction. In stark contrast, individuals who maintained treatment throughout the year achieved an average weight loss of 11.9%. Among this subset, those on high maintenance doses attained even more pronounced decreases, with semaglutide recipients losing approximately 13.7% and tirzepatide recipients achieving an impressive 18.0% reduction. These figures underscore the crucial role of both continued therapy and appropriate dosing in realizing the full potential of these pharmacologic agents.

The heterogeneity in patient response also aligned with other demographic and medication-specific factors. The data indicated that female patients had higher likelihoods of achieving significant weight loss, defined as a reduction of 10% or more, compared to their male counterparts. Moreover, tirzepatide was more effective than semaglutide at inducing such clinically meaningful weight reductions. These findings hint at possible sex-related physiological differences in drug metabolism or responsiveness, as well as intrinsic differences between the two agonists’ mechanisms of action.

Beyond weight parameters, the study turned attention to glycemic control, particularly among the subgroup of patients with prediabetes. In this vulnerable population, medication adherence was closely linked to the normalization of blood sugar levels, measured by the biomarker hemoglobin A1c (HbA1c). Only one-third of those who discontinued treatment early reverted to normal glycemic ranges, compared to nearly 42% of late discontinuers. However, a significant 67.9% of patients who continued treatment throughout achieved HbA1c levels consistent with normoglycemia. As type 2 diabetes constitutes one of the most common and severe complications of obesity, these findings emphasize the dual metabolic benefits of sustained GLP-1 receptor agonist therapy.

The study’s lead author, Dr. Hamlet Gasoyan of the Cleveland Clinic’s Center for Value-Based Care Research, emphasized the real-world implications of these conclusions, noting that despite robust efficacy demonstrated in clinical trials, the effectiveness of semaglutide and tirzepatide in everyday settings is undermined by factors such as medication discontinuation and suboptimal dosing. He highlighted the necessity for clinicians and patients to collaboratively address these issues to maximize therapeutic outcomes.

Further exploration of the reasons underpinning widespread discontinuation revealed a constellation of barriers common to medications for chronic conditions. Cost emerged as a paramount concern, with insurance coverage limitations frequently cited. Patients also reported adverse side effects and challenges related to medication supply shortages. In response, the research team is planning follow-up investigations to quantitatively and qualitatively dissect these drivers, aiming to inform policy changes and support mechanisms that could enhance treatment continuity.

An intriguing observation was that despite the significant differences in weight loss related to discontinuation, the trajectories of weight among patients who ceased treatment were relatively stable over time. This stability suggests that individuals may be employing additional weight management strategies post-discontinuation — a hypothesis that will be a focus of future studies. Understanding these compensatory behaviors could provide insights into holistic approaches combining pharmacotherapy with lifestyle or alternative interventions.

This investigation provides critical evidence on how the promising benefits of GLP-1 receptor agonists for obesity management translate outside the controlled environment of trials. It serves as a reminder that clinical effectiveness hinges not only on drug pharmacodynamics but also on factors like adherence, dosing regimens, economic considerations, and patient support systems. In the context of a global obesity epidemic and its interlinked metabolic diseases, optimizing the real-world use of agents like semaglutide and tirzepatide could have substantial public health implications.

The foundational importance of this research is heightened by the prevalence of severe obesity and prediabetes among the studied population — groups at markedly elevated risk for diabetes and cardiovascular disease. As the obesity and type 2 diabetes crises intensify worldwide, these findings advocate for more nuanced, patient-centered management strategies that anticipate and mitigate obstacles to sustained treatment.

In conclusion, Cleveland Clinic’s retrospective analysis throws into sharp relief the challenges of translating clinical trial success into real-world benefits for patients battling obesity and its metabolic sequelae. It challenges healthcare providers, payers, and policymakers to consider how best to support patients in maintaining high-dose, long-term GLP-1 receptor agonist therapy while addressing logistical and financial barriers. Through such multifaceted efforts, the promise of these innovative therapies might be fully realized, curbing obesity’s immense toll and improving quality of life for millions.

Subject of Research: The real-world effectiveness of semaglutide and tirzepatide in weight loss and glycemic control among patients with severe obesity, focusing on medication discontinuation and maintenance dosage impact

Article Title: Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status

News Publication Date: 10-Jun-2025

Web References:

• Cleveland Clinic Center for Value-Based Care Research
• Obesity Journal DOI

References:
Gasoyan H, et al. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity. 2025 Jun 10. DOI: 10.1002/oby.24331

Keywords: Weight loss, Medical treatments, Semaglutide, Tirzepatide, Obesity, GLP-1 receptor agonists, Glycemic control, Prediabetes, Type 2 diabetes, Medication adherence, Maintenance dosage, Real-world evidence